North America In-vitro Diagnostics Market to Grow at a CAGR of 4.7% During the Period 2024-2032, Driven by Need for Effective and Efficient Detection Technologies

In-vitro diagnostics (IVD) refer to tests carried out on samples such as blood or tissue taken from the human body. In vitro diagnostics can detect diseases, infections, or other conditions, and may be used to monitor a person’s overall health to help treat, cure, or prevent illnesses. In-vitro diagnostics may also be employed in precision medicine to recognize patients likely to benefit from particular treatments or therapies. Such in-vitro diagnostics could include next generation sequencing tests, which scan an individual’s DNA to detect genomic variations. Some tests are carried out in laboratory or other health professional settings; others may be performed by consumers at home by themselves.

In-vitro diagnostic devices (IVDs) determine a significant percentage of clinical decision. Such devices aid in the identification, diagnosis and monitoring of illness or other conditions and assist in ascertaining states of health; in-vitro diagnostic devices seek to offer quicker, smaller, and more cost-effective tools that allow more accurate diagnosis and point-of-care testing or self-testing. Sequencing technologies and multi-omic analysis offer an extensive representation for personalised disease diagnosis. In-vitro diagnostic devices (IVDs) play a vital role in the selection of suitable therapeutic interventions in healthcare delivery, particularly with advancements in personalized medicine. In-vitro diagnostic products are seen as a subgroup of medical devices in the USA, regulated by the Food and Drug Administration (FDA).

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Artificial intelligence (AI) and cloud services also offer cost-effective solutions for limited-resource settings. Advanced technologies in laboratory medicine, including genetic sequencing, liquid biopsy, microfluidics and mass spectrometry technologies mirror such developments. Liquid biopsy allows a non-invasive, real-time tool to diagnose cancer early. Microfluidics and other micro/nano devices offer solutions to system integration and enable smaller instruments. Mass spectrometry aids in the achievement of quick, high-throughput and high-sensitivity testing. Such solutions are expected to stimulate the North America in-vitro diagnostics market.

Leading companies are looking to expand capabilities and develop advanced solution. For example, in 2019, QIAGEN and Illumina joined forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration. For Illumina, the collaboration with Qiagen was set to add long-term expansion potential, specifically in the expanding market for companion diagnostics for targeted cancer therapies and immuno-oncology. Such developments are expected to drive the North America in-vitro diagnostics market.

In 2022, bioMérieux announced that it had finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that had developed a rapid antimicrobial susceptibility test (AST) system that delivered phenotypic AST directly from positive blood cultures. With the acquisition, bioMérieux sought to further develop its global leadership in clinical microbiology, bringing major innovation to the market and strengthen its fight against antimicrobial resistance.

Key Findings of the Report:

• The North America in-vitro diagnostics market is expected to be driven by the need for effective and efficient detection technologies.

• Advanced solutions are expected to boost market growth.

Market Analysis by Product and Service, Technology, Application, and Country:

• By product and service, the market is segmented into Reagents and Kits, Instruments, and Software and Services.

• By technology, the market is divided into Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Haematology, Blood Glucose Self-Monitoring, Coagulation and Haemostasis, Urinalysis, and Others.

• By application, the market is divided into Infectious Diseases, Diabetes, Oncology, Cardiology, Autoimmune Diseases, Nephrology, and Others.

• By country, the market is classified into United States and Canada.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.